CN1809552A - 大麻素衍生物、其制备方法和用途 - Google Patents

大麻素衍生物、其制备方法和用途 Download PDF

Info

Publication number
CN1809552A
CN1809552A CNA2004800174008A CN200480017400A CN1809552A CN 1809552 A CN1809552 A CN 1809552A CN A2004800174008 A CNA2004800174008 A CN A2004800174008A CN 200480017400 A CN200480017400 A CN 200480017400A CN 1809552 A CN1809552 A CN 1809552A
Authority
CN
China
Prior art keywords
compound
phenyl
group
acceptor
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800174008A
Other languages
English (en)
Chinese (zh)
Inventor
B·M·摩尔二世
A·M·费雷拉
M·柯利施那姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of CN1809552A publication Critical patent/CN1809552A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2004800174008A 2003-05-20 2004-05-20 大麻素衍生物、其制备方法和用途 Pending CN1809552A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47231603P 2003-05-20 2003-05-20
US60/472,316 2003-05-20

Publications (1)

Publication Number Publication Date
CN1809552A true CN1809552A (zh) 2006-07-26

Family

ID=33539041

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800174008A Pending CN1809552A (zh) 2003-05-20 2004-05-20 大麻素衍生物、其制备方法和用途

Country Status (10)

Country Link
US (2) US7169942B2 (enExample)
EP (1) EP1633733B1 (enExample)
JP (1) JP2007501279A (enExample)
CN (1) CN1809552A (enExample)
AT (1) ATE496901T1 (enExample)
AU (1) AU2004249669B2 (enExample)
CA (1) CA2526103A1 (enExample)
DE (1) DE602004031221D1 (enExample)
DK (1) DK1633733T3 (enExample)
WO (1) WO2004113320A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103110582A (zh) * 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
CN108137526A (zh) * 2015-07-10 2018-06-08 诺拉姆科有限公司 用于生产大麻二酚和△-9-四氢大麻酚的方法
CN110035774A (zh) * 2016-09-29 2019-07-19 耶路撒冷希伯来大学伊森姆研究发展有限公司 大麻素的可稀释制剂及其制备方法
CN110269839A (zh) * 2019-06-15 2019-09-24 云南飞久逍科技有限公司 一种大麻二酚cbd及其纳米乳在荨麻疹或/和鼻炎制剂中的应用
CN111587111A (zh) * 2017-08-27 2020-08-25 罗得技术公司 用于治疗眼科病症的药物组合物
CN113164830A (zh) * 2018-08-20 2021-07-23 贝索制药有限责任公司 大麻素的制备方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7824855B2 (en) * 2004-03-26 2010-11-02 Fujifilm Corporation Method for selectively separating and purifying RNA and method for separating and purifying nucleic acid
USRE46558E1 (en) 2005-04-28 2017-09-26 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
NZ601567A (en) 2005-09-29 2013-03-28 Albany Molecular Res Inc Process for production of delta-9-tetrahydrocannabinol
DE102005062098A1 (de) * 2005-12-22 2007-06-28 Merck Patent Gmbh Oxaphenanthren-Derivate
MX2008011013A (es) * 2006-02-28 2008-10-23 Paloma Pharmaceuticals Inc Composiciones y metodos para tratar enfermedades caracterizadas por proliferacion celular y angiogenesis.
CA2679373A1 (en) 2007-03-02 2008-09-12 The University Of Tennessee Research Foundation Tri-aryl/heteroaromatic cannabinoids and use thereof
AU2009228303B2 (en) * 2008-03-25 2015-08-13 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
US8124771B2 (en) * 2008-05-19 2012-02-28 University Of Tennessee Research Foundation Pyridine classical cannabinoid compounds and related methods of use
US8389534B2 (en) * 2008-05-19 2013-03-05 The University Of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use
WO2009143183A1 (en) * 2008-05-19 2009-11-26 University Of Tennessee Research Foundation, The Pyrimidine non-classical cannabinoid compounds and related methods of use
EP2299819A4 (en) * 2008-05-19 2011-07-20 Univ Tennessee Res Foundation NONCLASSICAL PYRIDINE CANNABINOID COMPOUNDS AND ASSOCIATED METHODS FOR THEIR USE
US8349876B2 (en) * 2008-05-19 2013-01-08 The University Of Tennesee Research Foundation Pyridine non-classical cannabinoid compounds and related methods of use
US8022078B2 (en) * 2008-05-19 2011-09-20 University Of Tennessee Research Foundation Pyrimidine classical cannabinoid compounds and related methods of use
US8476439B2 (en) 2008-05-19 2013-07-02 The University Of Tennessee Research Foundation Pyridine classical cannabinoid compounds and related methods of use
EP2309858A4 (en) 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
WO2015200049A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US20180169061A1 (en) * 2016-12-15 2018-06-21 Ascent Pharmaceuticals, Inc. Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
EP4037662A1 (en) * 2019-10-03 2022-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Liposomal cannabinoids and uses thereof
WO2021091908A1 (en) 2019-11-08 2021-05-14 Vella Bioscience, Inc. Peripherally acting cannabidiol(cbd)-containing compositions and uses thereof for enhancing female sexual function or treating female sexual disorders
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941782A (en) * 1972-04-27 1976-03-02 Sharps Associates Heterocyclic esters of benzopyrans
US3915996A (en) * 1972-10-16 1975-10-28 Abbott Lab Process for making benzopyrans
US3901926A (en) * 1973-04-02 1975-08-26 Abbott Lab Alkylphenyl benzopyrans
DE4100441A1 (de) * 1991-01-09 1992-07-16 Mack Chem Pharm Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
EP0971588B1 (en) 1997-01-21 2004-03-17 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
DE19706903A1 (de) 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
JP2001516361A (ja) 1997-03-18 2001-09-25 スミスクライン・ビーチャム・コーポレイション 新規カンナビノイド受容体作動薬
US5939429A (en) 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
EP1075470B1 (en) * 1998-05-04 2003-08-13 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
AU6088200A (en) 1999-07-12 2001-01-30 Virginia Commonwealth University Novel vasodilator cannabinoid analogs
FR2799124B1 (fr) 1999-10-01 2004-08-13 Sanofi Synthelabo Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
IL132661A (en) 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
FR2804604B1 (fr) 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US20040039048A1 (en) 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
AU783522B2 (en) * 2000-06-22 2005-11-03 Pharmos Corporation Novel non-psychotropic cannabinoids
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7067539B2 (en) 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US6509367B1 (en) 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
KR20050044417A (ko) 2001-11-14 2005-05-12 쉐링 코포레이션 카나비노이드 수용체 리간드
JP2005533809A (ja) 2002-06-19 2005-11-10 シェーリング　コーポレイション カンナビノイドレセプタアゴニスト
WO2004035566A1 (en) 2002-10-18 2004-04-29 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103110582A (zh) * 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
CN108137526A (zh) * 2015-07-10 2018-06-08 诺拉姆科有限公司 用于生产大麻二酚和△-9-四氢大麻酚的方法
CN110035774A (zh) * 2016-09-29 2019-07-19 耶路撒冷希伯来大学伊森姆研究发展有限公司 大麻素的可稀释制剂及其制备方法
CN111587111A (zh) * 2017-08-27 2020-08-25 罗得技术公司 用于治疗眼科病症的药物组合物
US11786463B2 (en) 2017-08-27 2023-10-17 Rhodes Technologies Pharmaceutical compositions for the treatment of ophthalmic conditions
CN111587111B (zh) * 2017-08-27 2023-12-19 罗得技术公司 用于治疗眼科病症的药物组合物
US12396948B2 (en) 2017-08-27 2025-08-26 Rhodes Technologies Pharmaceutical compositions for the treatment of ophthalmic conditions
CN113164830A (zh) * 2018-08-20 2021-07-23 贝索制药有限责任公司 大麻素的制备方法
CN113164830B (zh) * 2018-08-20 2023-02-21 贝索制药有限责任公司 大麻素的制备方法
CN110269839A (zh) * 2019-06-15 2019-09-24 云南飞久逍科技有限公司 一种大麻二酚cbd及其纳米乳在荨麻疹或/和鼻炎制剂中的应用

Also Published As

Publication number Publication date
EP1633733A4 (en) 2007-02-28
EP1633733A1 (en) 2006-03-15
AU2004249669B2 (en) 2008-05-22
JP2007501279A (ja) 2007-01-25
WO2004113320A1 (en) 2004-12-29
ATE496901T1 (de) 2011-02-15
DE602004031221D1 (de) 2011-03-10
US7169942B2 (en) 2007-01-30
US20040242593A1 (en) 2004-12-02
US20070167514A1 (en) 2007-07-19
DK1633733T3 (da) 2011-05-16
EP1633733B1 (en) 2011-01-26
AU2004249669A1 (en) 2004-12-29
CA2526103A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
CN1809552A (zh) 大麻素衍生物、其制备方法和用途
CN1036920C (zh) 含杂环碳酸衍生物
CN1077574C (zh) 托烷衍生物,其制备和应用
CN1041087C (zh) 芳基乙酰胺及其制备方法和应用
CN1176651C (zh) N-(3-苯并呋喃基)脲衍生物
US8383615B2 (en) Azetidine 2-carboxamide derivatives which modulate the CB2 receptor
CN1129451A (zh) 血管收缩剂二氢苯并吡喃衍生物
CN1045776C (zh) 吡啶环取代的噻唑烷和噁唑烷以及它们作为降血糖药的用途
CN1106811A (zh) 哌啶和哌嗪衍生物
CN1333698A (zh) 联合化学疗法
CN1090279A (zh) 用于治疗hiv以及其他逆转录病毒的吡喃-2-酮及5，6-二氢吡喃-2-酮
CN1738797A (zh) 取代的芳基硫脲和相关的化合物,病毒复制的抑制剂
CN1774433A (zh) 作为胰高血糖素受体拮抗剂的取代的3－氰基噻吩乙酰胺
CN1018614B (zh) 制备含n-杂环基-4-哌啶胺类的抗组胺组合物的方法
CN1835948A (zh) 2－酰基氨基噻唑衍生物或其盐
CN1244578C (zh) 取代的苯并呋喃－2－甲酰胺衍生物
CN100351237C (zh) 杂环化合物及其制备方法和含该化合物的药物组合物以及其在医药中的用途
CN1133044A (zh) 抑制精神活动的方法
CN1153766C (zh) 新的硝酮化合物，其制备方法以及含有它们的药物组合物
CN85108120A (zh) 三环吡啶衍生物的制备及其应用
CN1310911C (zh) 作为脑缺血性疾病和cns疾病治疗剂的哌嗪苯并噻唑
CN1076696A (zh) 药用化合物
CN1043990C (zh) 咪唑啉酮衍生物、其酸的加成盐及老年痴呆症的治疗药物
CN1099752A (zh) 新型酰氨烷基-和亚氨烷基-哌嗪
CN1107843A (zh) 二氢化茚衍生物和其制法及合成该衍生物的中间体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20060726